Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05288023 · ClinicalTrials.gov registry record · Phase 4
Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)
A Phase 4 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 4
- Development phase
- 169,707
- Enrollment target
NCT05288023 is a Phase 4 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 169,707 participants.
The verdict
NCT05288023, a Phase 4 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 169,707 participants
- Enrollment target
Study Summary
The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings. The proposed trial aims to demonstrate and evaluate large-scale implementation of azithromycin to children aged 1-11 months old in the context of a programmatic setting while monitoring mortality and resistance antimicrobial resistance.
Interventions
- DRUG Azithromycin for Oral Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169,707 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2024-01-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05288023
The ClinicalTrials.gov registry entry for NCT05288023 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 169,707 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azithromycin for Oral Suspension is the first listed.
NCT05288023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05288023 about?
NCT05288023 is a clinical study titled "Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)". The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high ...
What is the current status of trial NCT05288023?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 169,707 participants. The study started on 2022-12-01. Estimated completion is 2024-01-15.
What interventions are being tested in trial NCT05288023?
The interventions under investigation include: Azithromycin for Oral Suspension (DRUG).
Who is sponsoring clinical trial NCT05288023?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.